This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical, Inc. (ISRG) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $490.38, marking a +2% move from the previous day.
Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?
by Zacks Equity Research
ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
by Zacks Equity Research
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Labcorp Stock Gains From Biopharma Business Amid FX Woe
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Wall Street Analysts See Intuitive Surgical (ISRG) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Intuitive Surgical, Inc. (ISRG) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $484.76, denoting a -1.33% change from the preceding trading day.
Stock Market News for Oct 1, 2024
by Zacks Equity Research
Wall Street ended the third quarter on a strong note as investors seemed much more confident in the Federal Reserve's ability to achieve a soft landing for the U.S. economy.
Stocks to Buy and Hold for 5 Years
by Tracey Ryniec
What if you fell asleep and woke up 5 years later? Would you feel confident in your stock portfolio?
Intuitive Surgical, Inc. (ISRG) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $484.39, making no change from the previous trading session.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Intuitive Surgical, Inc. (ISRG) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $490.01, denoting a +1.64% change from the preceding trading day.
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Intuitive Surgical (ISRG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Intuitive Surgical, Inc. (ISRG) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $483.32, signifying a -1.64% move from its prior day's close.
Is Phibro Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
by Zacks Equity Research
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
KIDS Stock Gains From Its New Enabling Technologies Division Launch
by Zacks Equity Research
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte
by Zacks Equity Research
Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article
Zacks Investment Ideas feature highlights: Intuitive Surgical, SharkNinja and DaVita
by Zacks Equity Research
Intuitive Surgical, SharkNinja and DaVita have been highlighted in this Investment Ideas article.
3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost
by Urmimala Biswas
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.